AACR 2024: PDC*line Pharma presents interim clinical results from last cohort of patients in phase I/II trial with PDC*lung01 cancer vaccine
Intermediary results of high dose PDC*lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patients
Combination of high dose PDC*lung01 with pembrolizumab in 19